No human safety profile has been established beyond early-phase trials, and this compound is not approved for therapeutic use
Key Takeaways: GLP-1 vs GIP Both are incretin hormones released by your intestines after eating GLP-1 primarily affects appetite, gastric emptying, and insulin secretion GIP influences insulin secretion, glucagon regulation, and fat metabolism Single GLP-1 agonists (semaglutide) produce 14.9% average weight loss Dual GLP-1/GIP agonists (tirzepatide) produce 22.5% average weight loss The dual action appears to create additive rather than merely overlapping effects Both receptor types play important roles in metabolic regulation Understanding the difference helps explain why tirzepatide shows superior results What Are Incretin Hormones
Sterility testing confirming complete absence of microbial contaminants
Conclusion Choosing between tirzepatide injections or oral drops comes down to your personal needs and comfort level
Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus
No severe side effects have been observed in early studies
